TY - JOUR
T1 - Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor
T2 - Childhood cancer survivor study
AU - Packer, Roger J.
AU - Gurney, James G.
AU - Punyko, Judy A.
AU - Donaldson, Sarah S.
AU - Inskip, Peter D.
AU - Stovall, Marilyn
AU - Yasui, Yutaka
AU - Mertens, Ann C.
AU - Sklar, Charles A.
AU - Nicholson, H. Stacy
AU - Zeltzer, Lonnie K.
AU - Neglia, Joseph P.
AU - Robison, Leslie L.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - Purpose: To describe the neurologic and neurosensory deficits in children with brain tumors (BTs), compare incidence of these deficits with that of a sibling control group, and evaluate the factors associated with the development of these deficits. Patients and Methods: Detailed questionnaires were completed on 1,607 patients diagnosed between 1970 and 1986 with a primary CNS tumor. Neurosensory and neurologic dysfunctions were assessed and results compared with those of a sibling control group. Medical records on all patients were abstracted, including radiotherapy dose and volume. Results: Seventeen percent of patients developed neurosensory impairment. Relative to the sibling comparison group, patients surviving BTs were at elevated risk for hearing impairments (relative risk [RR], 17.3; P = < .0001), legal blindness in one or both eyes (RR, 14.8; P = < .0001), cataracts (RR, 11.9; P = < .0001), and double vision (RR, 8.8; P = < .0001). Radiation exposure greater than 50 Gy to the posterior fossa was associated with a higher likelihood of developing any hearing impairment. Coordination and motor control problems were reported in 49% and 26%, respectively, of survivors. Children receiving at least 50 Gy to the frontal brain regions had a moderately elevated risk for motor problems (RR, 2.0; P < .05). Seizure disorders were reported in 25% of patients, including 6.5% who had a late first occurrence. Radiation dose of 30 Gy or more to any cortical segment of the brain was associated with a two-fold elevated risk for a late seizure disorder. Conclusion: Children surviving BTs are at significant risk for both early and late neurologic or neurosensory sequelae. These sequelae need to be prospectively monitored.
AB - Purpose: To describe the neurologic and neurosensory deficits in children with brain tumors (BTs), compare incidence of these deficits with that of a sibling control group, and evaluate the factors associated with the development of these deficits. Patients and Methods: Detailed questionnaires were completed on 1,607 patients diagnosed between 1970 and 1986 with a primary CNS tumor. Neurosensory and neurologic dysfunctions were assessed and results compared with those of a sibling control group. Medical records on all patients were abstracted, including radiotherapy dose and volume. Results: Seventeen percent of patients developed neurosensory impairment. Relative to the sibling comparison group, patients surviving BTs were at elevated risk for hearing impairments (relative risk [RR], 17.3; P = < .0001), legal blindness in one or both eyes (RR, 14.8; P = < .0001), cataracts (RR, 11.9; P = < .0001), and double vision (RR, 8.8; P = < .0001). Radiation exposure greater than 50 Gy to the posterior fossa was associated with a higher likelihood of developing any hearing impairment. Coordination and motor control problems were reported in 49% and 26%, respectively, of survivors. Children receiving at least 50 Gy to the frontal brain regions had a moderately elevated risk for motor problems (RR, 2.0; P < .05). Seizure disorders were reported in 25% of patients, including 6.5% who had a late first occurrence. Radiation dose of 30 Gy or more to any cortical segment of the brain was associated with a two-fold elevated risk for a late seizure disorder. Conclusion: Children surviving BTs are at significant risk for both early and late neurologic or neurosensory sequelae. These sequelae need to be prospectively monitored.
UR - http://www.scopus.com/inward/record.url?scp=0141799966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141799966&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.01.202
DO - 10.1200/JCO.2003.01.202
M3 - Article
C2 - 12947060
AN - SCOPUS:0141799966
SN - 0732-183X
VL - 21
SP - 3255
EP - 3261
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 17
ER -